By Adjunct Professor Michael Leonard Friedlander

Book Chapters

Berek JS; Renz M; Friedlander ML; Bast RC, 2022, 'Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer', in , Wiley, pp. 1 - 23, http://dx.doi.org/10.1002/9781119000822.hfcm105.pub2

Berek JS; Renz M; Friedlander ML; Bast RC, 2022, 'Nonepithelial Ovarian Malignancies', in , Wiley, pp. 1 - 18, http://dx.doi.org/10.1002/9781119000822.hfcm106.pub2

Christie EL; Freimund AE; Fereday S; Alsop K; Hoang T; Pishas K; Au-Yeung G; Friedlander M; Bowtell DD, 2020, 'The development of drug resistance through reversion mutation in BRCA genes in ovarian cancer', in Overcoming Ovarian Cancer Chemoresistance, pp. 43 - 53, http://dx.doi.org/10.1016/B978-0-12-819840-7.00013-3

Amant F; Hensley M; Pautier P; Friedlander M; Sagae S; Fujiwara K; Rigaud DB; Lorusso D; Ray-Coquard I, 2020, 'Management of Rare Uterine Malignant Tumors', in Mirza MR (ed.), MANAGEMENT OF ENDOMETRIAL CANCER, SPRINGER INTERNATIONAL PUBLISHING AG, pp. 277 - 312, http://dx.doi.org/10.1007/978-3-319-64513-1_19

Berek JS; Friedlander ML; Bast RC, 2017, 'Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer', in , Wiley, pp. 1 - 27, http://dx.doi.org/10.1002/9781119000822.hfcm105

Berek JS; Friedlander ML; Bast RC, 2017, 'Nonepithelial Ovarian Malignancies', in , Wiley, pp. 1 - 17, http://dx.doi.org/10.1002/9781119000822.hfcm106

Friedlander ML; Markman M, 2014, 'Chemotherapy', in Berek and Hacker S Gynecologic Oncology Sixth Edition, pp. 58 - 84

Berek JS; Friedlander ML; Hacker NF, 2014, 'Epithelial ovarian, fallopian tube, and peritoneal cancer', in Berek and Hacker S Gynecologic Oncology Sixth Edition, pp. 464 - 529

Berek JS; Friedlander ML; Hacker NF, 2014, 'Germ cell and nonepithelial ovarian cancer', in Berek and Hacker S Gynecologic Oncology Sixth Edition, pp. 530 - 559

Hacker NF; Friedlander ML, 2014, 'Uterine cancer', in Berek and Hacker S Gynecologic Oncology Sixth Edition, pp. 390 - 442

Friedlander M; Thigpen JT, 2014, 'Response as a measure of treatment efficacy in clinical trials: Should recist be abandoned?', in Controversies in the Management of Gynecological Cancers, pp. 91 - 100, http://dx.doi.org/10.1007/978-0-85729-910-9_9

Berek JS; Longacre T; Friedlander M, 2011, 'Ovarian, Fallopian Tube and Peritoneal Cancer', in Berek JS (ed.), Berek and Novak's Gynecology, Royal College of Obstetricians and Gynaecologists, UK, pp. 1350 - 1427

Gainford M; Friedlander M, 2011, 'Squamous Cell Carcinomas Arising From Dermoids', in Reed N; Green JA; Gershenson DM; Siddiqui N; Connor R (ed.), Rare and Uncommon Gynecological Cancers, Springer, USA, pp. 131 - 134

Hacker NF; Friedlander ML, 2010, 'Breast Disease: A Gynecologic Perspective', in Hacker &amp Moore's Essentials of Obstetrics and Gynecology, Elsevier, pp. 326 - 331, http://dx.doi.org/10.1016/b978-1-4160-5940-0.00029-1

Friedlander ML; Gershenson D; Hacker NF; Arjun G; Smitj ; Barber HM, 1997, 'Stage IIC ovarian cancer which is completely resected. In expert consultations in gynecological cancers.', in Stage IIC ovarian cancer which is completely resected. In expert consultations in gynecological cancers., Mercel Dekker, New York, pp. 263 - 270

Journal articles

Zwimpfer TA; Fereday S; Pandey A; Ariyaratne D; Jayawardana MW; Twomey L; Laumont CM; Kennedy CJ; Bolithon A; Meagher NS; Milne K; Hamilton P; Alsop J; Antoniou AC; Au-Yeung G; Beckmann MW; Berrington de Gonzalez A; Bisinotto C; Blome F; Bodelon C; Boros J; Brand AH; Carney ME; Cazorla-Jiménez A; Chiu DS; Christie EL; Chudecka-Głaz A; Coulson P; Cushing-Haugen KL; Cybulski C; Darcy KM; David C; Davidson T; Ekici AB; Elishaev E; Emons J; Engler T; Farrell R; Fischer A; García-Closas M; Gentry-Maharaj A; Ghatage P; Glasspool R; Harter P; Hartkopf AD; Hartmann A; Heikaus S; Hernandez BY; Hettiaratchi A; Heublein S; Huntsman DG; Jimenez-Linan M; Jones ME; Kang E; Kaznowska E; Kluz T; Kommoss FKF; Konecny G; Kruitwagen RFPM; Kwon J; Lambrechts D; Lee CH; Lester J; Leung SCY; Leung Y; Linder A; Lissowska J; Loverix L; Lubiński J; Mateoiu C; McNeish IA; Moubarak M; Nelson GS; Nevins N; Olawaiye AB; Olbrecht S; Orsulic S; Osorio A; Quinn CM; Mohan GR; Ray-Coquard I; Rodríguez-Antona C; Roxburgh P; Ruebner M; Salfinger SG; Samra S; Schoemaker MJ; Sinn HP; Sonke GS; Steele L; Stewart CJR; Talhouk A; Tan A; Tarney CM; Taylor SE; Van de Vijver KK; van der Aa MA; Van Gorp T; Van Nieuwenhuysen E; Van-Wagensveld L, 2026, 'Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma', Nature Communications, 17, http://dx.doi.org/10.1038/s41467-026-71134-3

Woodford R; Lord S; Lin F; Papenfuss AT; Marschner I; Thomas D; Friedlander M; Scott C; Simes J; Lee CK, 2026, 'Enhancing Outcome Measurement in Oncology Clinical Trials Through Artificial Intelligence: A Scoping Review', JCO Clinical Cancer Informatics, 10, http://dx.doi.org/10.1200/CCI-26-00014

Woodford R; Lord S; Decaria A; Simes J; Friedlander M; Marschner IC; Lee CK, 2026, 'Informative censoring in maintenance therapy trials for advanced ovarian cancer: An empirical assessment of its impact on treatment benefit', European Journal of Cancer, 235, http://dx.doi.org/10.1016/j.ejca.2026.116231

Majidi A; Na R; Jordan SJ; Ross TL; DeFazio A; Friedlander M; Grant P; Webb PM, 2026, 'Angiotensin converting enzyme inhibitors and angiotensin receptor blockers and ovarian cancer survival: the Ovarian cancer Prognosis And Lifestyle (OPAL) study', Cancer Epidemiology, 100, http://dx.doi.org/10.1016/j.canep.2025.102961

Virassamy B; Caramia F; Savas P; Harris MA; Pan JW; Wang J; Brown E; O’malley MMR; van Geelen CT; Hun M; Burn TN; Sant S; Ballan JD; Kay J; Lara Gonzalez LE; Clarke K; Aw Yeang HX; Idrizi R; Jana M; Challice DJ; Salgado R; Thorne H; Poliness C; Nightingale S; Teo SH; Speed TP; Visvader J; Neeson PJ; Darcy PK; Mackay LK; Loi S; Amor D; Andrews L; Antill Y; Balleine R; Beesley J; Bennett I; Bogwitz M; Bodek S; Botes L; Brennan M; Brown M; Buckley M; Burke J; Butow P; Caldon L; Campbell I; Cao M; Chakrabarti A; Chauhan D; Chauhan M; Chenevix-Trench G; Christian A; Cohen P; Colley A; Crook A; Cui J; Courtney E; Cummings M; Dawson SJ; Defazio A; Delatycki M; Dickson R; Dixon J; Edwards S; Farshid G; Fellows A; Fenton G; Field M; Flanagan J; Fong P; Forrest L; Fox S; French J; Friedlander M; Gaff C; Gattas M; George P; Greening S; Harris M; Hart S; Harraka P; Hayward N; Hopper J; Hoskins C; Hunt C; James P; Jenkins M; Kidd A; Kirk J; Koehler J; Kollias J; Lakhani S; Lawrence M; Lee J; Li S; Lindeman G; Lippey J; Lipton L; Lobb L, 2026, 'Parity and lactation induce T-cell-mediated breast cancer protection', Nature, 649, pp. 449 - 459, http://dx.doi.org/10.1038/s41586-025-09713-5

Chiang JCB; Makrynioti D; Goldstein D; Naduvilath TJ; Trinh T; O’Neill S; Hovey E; Lewis CR; Friedlander M; Au K; Alotaibi S; Park SB; Markoulli M; Krishnan AV, 2026, 'Dose-dependent neurotoxic chemotherapy and corneal nerve morphological changes', Clinical and Experimental Optometry, 109, pp. 929 - 937, http://dx.doi.org/10.1080/08164622.2025.2606161

Evans HE; Firriolo AM; Houweling R; Kelada L; Stannard G; Frawley J; McGill BC; Ramus SJ; Lee YC; Friedlander M; Duggan J; Wakefield CE, 2026, 'Evaluating patient perspectives about the acceptability of a novel prognostic gene expression signature for high grade serous ovarian cancer: The OTTA-SPOT study', Gynecologic Oncology, 204, pp. 150 - 157, http://dx.doi.org/10.1016/j.ygyno.2025.11.023

Haggstrom L; Lee YC; Barretina-Ginesta MP; Jaeger A; Woelber L; Woopen H; Rhind M; Frenel JS; Aanum A; Bischof K; Mongillo M; Brodsky AL; Ledermann J; Ghezelayagh TS; Boere I; Kaiser S; Maximiano C; Rosengarten O; Safra T; Pertejo A; Cecere S; Ray-Coquard I; Lheureux S; Glasspool R; Gil-Martin M; Tookman L; Kim SI; Mittelstadt S; Corbellas Aparicio M; Palacio I; Martin-Lorente C; Kristeleit R; De La Cueva H; Ottevanger N; Quindós Varela M; Yoshida H; Link T; Gaba L; Marquina G; Burdett N; Johannet P; Reichenbach J; Park-Simon TW; Klecker PH; González-Martín A; Marth C; Liebrich C; Dzotsenidze L; Heublein S; Kasherman L; Perez C; Masvidal M; Guillén Sentís P; De Gregorio N; Hemptenmacher F; Hilpert F; Sehouli J; Scott C; Tucker KM; Dong J; Fortuno C; Spurdle AB; Friedlander M, 2026, 'Long-Term Outcomes in Patients with Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors', JAMA Oncology, http://dx.doi.org/10.1001/jamaoncol.2026.1924

Naidoo M; McNally O; Scott CL; Friedlander M; Cohen PA; Perera S; Lloyd M; Brand A; Richardson G; Bunting M; Mohan R; Oehler M; Hyde S; Jobling T; Farrell R; Rome R; Zalcberg J, 2026, 'Quality Matters: Linking Patterns of Care to Ovarian Cancer Survival in a National Gynae-Oncology Registry', JCO Oncology Practice, http://dx.doi.org/10.1200/OP-25-00664

Meagher NS; Hewage AH; Daniels B; Ruiz J; Turner V; Friedlander ML; Lee YC; Williams R; Litchfield M; Merritt MA; Defazio A; Cohen PA; Pearson S; Webb P, 2026, '125P Publicly funded testing for germline BRCA1/2 pathogenic variants in ovarian cancer in Australia: A population-based study', ESMO Open, 11, pp. 108172 - 108172, http://dx.doi.org/10.1016/j.esmoop.2026.108172

Dalrymple J; Symons R; Sjoquist KM; Lord SJ; Woodford R; Friedlander M; Simes RJ; Lee CK, 2026, 'Time to Treatment Failure as an End Point in Pragmatic Oncology Trials: Association With Progression-Free Survival Across Randomized Studies', JCO PRECISION ONCOLOGY, 10, http://dx.doi.org/10.1200/PO-26-00011

Lee CK; Kartikasari AER; Bound NT; Francis KE; Shield-Artin K; Bedo J; Nesic K; Diamante K; O’Connell RL; Madondo M; Cox M; Davies C; Deceneux C; Goodchild G; Jarratt A; Cassar E; Amer H; Kariyawasam UGIU; Lee YC; Lombard J; Baron-Hay S; Antill Y; Shannon C; Selva-Nayagam S; Beale P; Zebic D; Simon S; Linaker A; Quinn MA; Papenfuss AT; Wakefield MJ; Vandenberg CJ; Friedlander M; Scott CL; Plebanski M, 2025, 'Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial', Nature Communications, 16, http://dx.doi.org/10.1038/s41467-025-64130-6

Petousis S; Kahramanoglu I; Appenzeller-Herzog C; Angeles MA; Margioula-Siarkou C; Kacperczyk-Bartnik J; Bilir E; Chatzakis C; Caruso G; Bizzarri N; Dinas K; Bowtell DDL; Garsed DW; Ray-Coquard I; Ledermann JA; Friedlander M; Sotiriadis A; Heinzelmann-Schwarz V; Zwimpfer TA, 2025, 'PARP Inhibitor Maintenance After First-Line Chemotherapy in Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review and Meta-Analysis', JAMA Network Open, 8, pp. e2541648, http://dx.doi.org/10.1001/jamanetworkopen.2025.41648

Ngoi NYL; Choi CH; Zhu J; Lim D; Tan TZ; Sun H; Heong V; Ow SGW; Chay WY; Kim HS; Lim YW; Lim SE; Goss G; Goh JC; Kim JW; Friedlander M; Tai BC; Kim K; Tan DSP, 2025, 'Durvalumab versus Physician’s Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): A Multicenter, Randomized, Phase 2 Trial', Clinical Cancer Research, 31, pp. 3907 - 3915, http://dx.doi.org/10.1158/1078-0432.CCR-25-0201

Konstantinopoulos PA; Kim JW; Freyer G; Lee JY; Gaba L; Grisham RN; Colombo N; Wu X; Sehouli J; Cruz F; Cibula D; Monk BJ; Nyvang GB; Friedlander M; Lorusso D; Van Nieuwenhuysen E; Malik R; Glasspool R; Marth C; Leary A; Cortés-Salgado A; Zamagni C; Marmé F; Sufliarsky J; Hinson P; Zuradelli M; Wang C; Su F; Paule I; Miller M; Matulonis UA; González-Martín A, 2025, 'Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation', Journal of Clinical Oncology, 43, pp. 2908 - 2917, http://dx.doi.org/10.1200/JCO-25-00225

Renz M; Friedlander M; Berek JS, 2025, 'Cancer of the ovary, fallopian tube, and peritoneum: 2025 update', International Journal of Gynecology and Obstetrics, 171, pp. 6 - 35, http://dx.doi.org/10.1002/ijgo.70282

Gersekowski K; Defazio A; Friedlander M; Obermair A; Webb PM, 2025, 'Green tea consumption, primary treatment outcome and survival after a diagnosis of ovarian cancer', Journal of Epidemiology and Community Health, 79, pp. 684 - 690, http://dx.doi.org/10.1136/jech-2024-222687

Francis KE; Lord SJ; Simon S; Friedlander M; Gebski V; Simes J; Lee CK, 2025, 'Under the radar - Frequency, timing, duration, and trajectory of lower-grade adverse events in clinical trials of anti-cancer therapies', Oncologist, 30, http://dx.doi.org/10.1093/oncolo/oyaf230

Coleman RL; Fleming GF; Brady MF; Swisher EM; Steffensen KD; Friedlander M; Okamoto A; Moore KN; Leath CA; Cella D; Sun Z; Patel S; Tang Z; Ratajczak CK; Aghajanian C; Bookman MA, 2025, 'Veliparib concomitant with first-line chemotherapy and as maintenance therapy in ovarian cancer: Final overall survival and disease-related symptoms results', European Journal of Cancer, 225, http://dx.doi.org/10.1016/j.ejca.2025.115587

Friedlander ML; Anderson L; Lee YC, 2025, 'Erratum to ‘Controversies in the management of ovarian granulosa cell and Sertoli-Leydig cell tumors’ [International Journal of Gynecological Cancer Volume 35 Issue 3 (2025) 101668] (International Journal of Gynecological Cancer (2025) 35(3), (S1048891X25001938), (10.1016/j.ijgc.2025.101668))', International Journal of Gynecological Cancer, 35, http://dx.doi.org/10.1016/j.ijgc.2025.101953

Campbell R; Jeon M; Friedlander M; King MT; Obermair A; Bilic S; Brand A; Butow P; Codde J; Gebski V; Goh JC; Ives A; Lawson W; McNally O; Meniawy T; Mileshkin LR; Morton RL; Webb PM; Yates P; Cohen PA, 2025, '"The telehealth means I get distance from the hospital so I don't feel so much like a patient": A qualitative sub-study examining the acceptability of nurse-led follow-up for ovarian cancer via telehealth using the MOST-S26 to structure consultations', JOURNAL OF CLINICAL ONCOLOGY, 43, http://dx.doi.org/10.1200/JCO.2025.43.16_suppl.12099

Marth C; Moore RG; Bidziński M; Pignata S; Ayhan A; Rubio MJ; Beiner M; Hall M; Vulsteke C; Braicu EI; Sonoda K; Wu X; Frentzas S; Mattar A; Lheureux S; Chen X; Hasegawa K; Magallanes-Maciel M; Choi CH; Shalkova M; Kaen D; Wang PH; Berger R; Okpara CE; McKenzie J; Yao L; Orlowski R; Khemka V; Gilbert L; Makker V; Gomez Abuin G; Zamora LB; Alfie MS; Casarini IA; Harrison M; Ananda S; Shannon CM; Friedlander M; Meniawy T; Gao B; Baron-Hay S; Diakos C; Polterauer S; Petru E; De Bock M; Baurain JF; Van Gorp T; Altintas S; Lima JPDSN; De Freitas Junior R; Santana RO; De Melo AC; Franke FA; Zibetti Dal Molin G; Damian FB; Guedes JDC; Ellard S; Tinker A; Samouëlian V; Fortin S; Bessette P; Kolinsky M; Kumar Tyagi N; Ethier JL; MacKay H; Lim C; Pan L; An R; Zheng H; Wu Y; Zhu J; Yao S; Jia X; Huang Y; Lv W; Zhang Y; Zhou Q; Ma C; Chekerov R; Mach P; Witteler R; Marmè F; Cadoo K; Korach J; Levy T; Amnon A; Scollo P; Naglieri E; Zamagni C; Salutari V; Usami T; Nakamura K; Matsumoto K; Yamagami W; Kobayashi Y; Takano M; Kato H; Kikuchi A; Katsumata N, 2025, 'First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial', Journal of Clinical Oncology, 43, pp. 1083 - 1100, http://dx.doi.org/10.1200/JCO-24-01326

Friedlander ML; Anderson L; Lee YC, 2025, 'Controversies in the management of ovarian granulosa cell and Sertoli-Leydig cell tumors', International Journal of Gynecological Cancer, 35, http://dx.doi.org/10.1016/j.ijgc.2025.101668

Phillips KA; Kotsopoulos J; Domchek SM; Terry MB; Chamberlain JA; Bassett JK; Aeilts AM; Andrulis IL; Buys SS; Cui W; Daly MB; Eisen AF; Foulkes WD; Friedlander ML; Gronwald J; Hopper JL; John EM; Karlan BY; Kim RH; Kurian AW; Lubinski J; Metcalfe K; Nathanson KL; Singer CF; Southey MC; Symecko H; Tung N; Narod SA; Milne RL; Amor D; Andrews L; Antill Y; Balleine R; Beesley J; Bennett I; Bogwitz M; Bodek S; Botes L; Brennan M; Brown M; Buckley M; Burke J; Butow P; Caldon L; Campbell I; Cao M; Chakrabarti A; Chauhan D; Chauhan M; Chenevix-Trench G; Christian A; Cohen P; Colley A; Crook A; Cui J; Courtney E; Cummings M; Dawson SJ; Defazio A; Delatycki M; Dickson R; Dixon J; Edwards S; Farshid G; Fellows A; Fenton G; Field M; Flanagan J; Fong P; Forrest L; Fox S; French J; Friedlander M; Gaff C; Gattas M; George P; Greening S; Harris M; Hart S; Harraka P; Hayward N; Hopper J; Hoskins C; Hunt C; James P; Jenkins M; Kidd A; Kirk J; Koehler J; Kollias J; Lakhani S; Lawrence M; Lee J; Li S; Lindeman G; Lippey J; Lipton L; Lobb L; Loi S; Mann G, 2025, 'Hormonal Contraception and Breast Cancer Risk for Carriers of Germline Mutations in BRCA1 and BRCA2', Journal of Clinical Oncology, 43, pp. 422 - 431, http://dx.doi.org/10.1200/JCO.24.00176

Lee YC; Whitely A; Burling M; Anderson L; Cohen PA; Naidoo M; Richardson G; Perera S; Scott CL; Friedlander M; Brand A; McNally O; Hyde S; Bunting M; Jobling T; Zalcberg J; Rome R, 2025, 'Patterns of care and development of quality indicators in patients with non-epithelial and rare ovarian tumors in Australia: insights from the National Gynae-Oncology Registry', International Journal of Gynecological Cancer, 35, http://dx.doi.org/10.1016/j.ijgc.2024.100052

Na R; Jordan SJ; DeFazio A; Williams M; Livingstone K; Obermair A; Friedlander M; Grant P; Webb PM, 2025, 'Use of menopausal hormone therapy before and after diagnosis and ovarian cancer survival—A prospective cohort study in Australia', International Journal of Cancer, 156, pp. 280 - 292, http://dx.doi.org/10.1002/ijc.35154

Francis KE; Simon S; Gebski V; Joly F; Ledermann JA; Penson RT; Oza AM; Korach J; Lainez N; Cecere SC; Tasca G; Gropp-Meier M; Fujiwara K; Lowe ES; Friedlander M; Pujade-Lauraine E; Lee CK, 2025, 'Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer', Gynecologic Oncology, 192, pp. 50 - 55, http://dx.doi.org/10.1016/j.ygyno.2024.11.004

Pitiyarachchi O; Friedlander M, 2025, 'Age disparities in clinical trials of poly (ADP-ribose) polymerase (PARP) inhibitors in patients with high grade serous ovarian cancer: A wake up call to improving outcomes in older patients', Journal of Geriatric Oncology, 16, http://dx.doi.org/10.1016/j.jgo.2024.102152

Na R; Nagle CM; Bartsch S; Ibiebele TI; Williams M; Grant P; Friedlander ML; Webb PM, 2025, 'Use of Dietary Supplements Before, During and After Treatment for Ovarian Cancer: Results from the Ovarian Cancer Prognosis and Lifestyle (OPAL) Study', Nutrition and Cancer, 77, pp. 200 - 209, http://dx.doi.org/10.1080/01635581.2024.2408775

Shivasabesan G; Phung J; Francis K; Knights T; Perera S; Wan KM; Rome RM; Zalcberg JR; Friedlander ML; Lee YC, 2025, 'Bevacizumab use in Australian patients with epithelial ovarian cancer: A real-world study survival analysis', ANNALS OF ONCOLOGY, 36, pp. S1944 - S1944, http://dx.doi.org/10.1016/j.annonc.2025.10.1050

Makrynioti D; Bo Chiang JC; Goldstein D; Naduvilath T; Trinh T; O’Neill S; Hovey E; Lewis C; Friedlander M; Au K; Alotaibi S; Park SB; Markoulli M, 2025, 'Dose-dependent corneal nerve morphological changes due to neurotoxic chemotherapy: an in vivo corneal confocal microscopy study', Contact Lens and Anterior Eye, 48, pp. 102557 - 102557, http://dx.doi.org/10.1016/j.clae.2025.102557

Petousis S; Kahramanoglu I; Appenzeller-Herzog C; Kacperczyk-Bartnik J; Angeles MA; Bilir E; Caruso G; Friedlander M; Margioula-Siarkou C; Sotiriadis A; Heinzelmann-Schwarz V; Zwimpfer TA, 2025, 'Efficacy And Safety Of PARP Inhibitor Maintenance In Platinum-Sensitive Advanced-Stage Epithelial Ovarian Cancer: A Systematic Review And Meta-Analysis', INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 35, http://dx.doi.org/10.1016/j.ijgc.2024.100336

Nahm SH; Kiely BE; O'Connell RL; Lee YC; Davis A; Avall-Lundqvist E; Berek JS; Berton D; Donnellan P; Hilpert F; Joly F; Lanceley A; Ledermann JA; Okamoto A; Oza A; Pignata S; Sehouli J; King MT; Friedlander M; Stockler MR; Roncolato FT; GCIG Symptom Benefit Group , 2025, 'Prognostic significance and accuracy of oncologists' estimates of survival time in recurrent ovarian cancer.', Int J Gynecol Cancer, 35, pp. 100030, http://dx.doi.org/10.1016/j.ijgc.2024.100030

Pitiyarachchi O; Lee CK; Sim H-W; Oconnell R; Lanceley A; Lobbedez FJ; Hilpert F; Pignata S; Berton-Rigaud D; Kaminsky-Forrett M-C; Okamoto A; Yoshida Y; Lindemann K; Oza AM; Berek JS; Ledermann JA; Friedlander ML, 2025, 'Prognostic value of progression free status at 6 months on overall survival (OS) in platinum resistant ovarian cancer (PROC): Landmark analysis from the GCIG Symptom Benefit Study', ANNALS OF ONCOLOGY, 36, pp. S1941 - S1942, http://dx.doi.org/10.1016/j.annonc.2025.10.1041

Li T; Timmins HC; Horvath LG; Harrison M; Grimison P; Friedlander M; Marx G; Boyle F; Wyld D; Henderson R; King T; Baron-Hay S; Kiernan MC; Barnes EH; Goldstein D; Park SB, 2025, 'Risk factors for dose-limiting, chronic and severe chemotherapy-induced peripheral neuropathy', Clinical Neurophysiology, 176, pp. 2110921 - 2110921, http://dx.doi.org/10.1016/j.clinph.2025.2110921

Back to profile page